What is OTLK's market cap?

$112.50M, based on the Nov 4 close of $0.46.

Does Outlook Therapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of OTLK is sold short?

32.6M shares, 39.3% of float, as of Oct 15, 2026.

What sector is OTLK in?

Healthcare, in the Biotechnology industry.

NASDAQ · OTLKHealthcareBiotechnology

Outlook Therapeutics, Inc. Common Stock (OTLK)

$0.4621+0.46%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$0.47▼ 64.09% in range

Nov 3, 2025Low $0.20 · High $2.47Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Outlook Therapeutics closed at $0.46 on Nov 4, up 0.46%, 81.3% below its 52-week closing high. Volume of 2.7M shares was 0.71× its 20-day average (below normal).

Split-adjusted performance: -19.2% over one month, +99.4% over six months, -64.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $8.70K, down 99.4% from a year earlier, with a net margin of -233554.9%.

Short interest was 32.6M shares at the Oct 15 settlement, up 2.2% from the prior report (39.3% of float, 6.8 days to cover).

Market cap$112.5M243.4M shares

Revenue · quarter$8.7K−99.4% YoY

Diluted EPS$-0.15—

P/E · TTM—

Net margin-233,554.9%Gross -95.0%

Dividend yieldNone

52-week range0.20 – 2.47−81.3% from high

Volume2.7M0.71× 20-day avg

Volatility · 60d89.1%Annualised

Short % of float39.3%6.8 days to cover

Net cash-$7.0MCash $11.2M

Next earnings—Not scheduled

Split-adjusted performance

1W −15.2%1M −19.2%3M −52.5%6M +99.4%YTD −70.8%1Y −64.5%3Y −95.7%5Y −98.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum95

Revenue growth9

Net margin0

Value (low P/E)—

Size36

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →

Shares short32.6M+2.2% vs prior

Days to cover6.8Settled Oct 15

% of float39.3%

Short vol. 10d56.3%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
OTLKOutlook Therapeutics	$0.4621	+0.46%	+99.4%	−99.4%	−233554.9%	—	$112.5M
VYGRVoyager Therapeutics	$1.87	+2.19%	−55.2%	−39.1%	−773.2%	—	$115.2M	Compare
ENGNenGene Therapeutics	$1.72	+6.17%	−80.6%	—	—	—	$115.3M	Compare
BDTXBlack Diamond Therapeutics	$1.90	+4.97%	−32.6%	—	—	—	$109.2M	Compare
LENZLENZ Therapeutics	$3.46	−1.14%	−64.3%	+9.7%	−581.8%	—	$108.7M	Compare
ARMPArmata Pharmaceuticals	$3.14	+1.62%	−65.3%	+15.7%	2953.8%	—	$116.8M	Compare
AVXLAnavex Life Sciences	$1.26	+5.00%	−62.3%	—	—	—	$116.8M	Compare
NMRANeumora Therapeutics	$0.5660	−0.86%	−75.7%	—	—	—	$106.3M	Compare
HUMAHumacyte	$0.4500	+2.16%	−54.2%	+34.9%	−9064.5%	—	$125.0M	Compare

News about Outlook Therapeutics

All news →

LYTENAVA Sales Forecast and Market Size Analysis 2020-2034: FDA Setback Shapes LYTENAVA Commercial PathGlobeNewswire Inc. · Sep 10, 2026▼ Negative Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMDGlobeNewswire Inc. · Jul 24, 2026▲ Positive Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswire Inc. · May 28, 2026Neutral Outlook Therapeutics Announces Proposed Public OfferingBenzinga · Mar 23, 2026Neutral

Quick answers

What does Outlook Therapeutics do?: Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom.
What is OTLK's market cap?: $112.50M, based on the Nov 4 close of $0.46.
Does Outlook Therapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of OTLK is sold short?: 32.6M shares, 39.3% of float, as of Oct 15, 2026.
What sector is OTLK in?: Healthcare, in the Biotechnology industry.

About Outlook Therapeutics

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

HQ: Iselin, NJ17 employeesListed May 13, 2016outlooktherapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology